XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Cash Flows
 12 Months Ended
Dec. 31, 2023
USD ($)
shares
Dec. 31, 2022
USD ($)
shares
Cash flows from operating activities:    
Net income $ 13,177,526 $ 1,485,528
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 5,425,739 5,465,015
Stock compensation 989,515 1,204,106
Bad debt expense 28,880 73,055
Gain on sale of real estate assets, net (3,240,200) (5,079,912)
Gain on deconsolidation of SPAC investment (40,321,483) 0
Net change in fair value SPAC Trust Account (1,414,420) (1,976,183)
Impairment of goodwill and real estate assets 3,247,097 0
Amortization of financing costs 345,880 240,090
Amortization of below-market leases (4,974) (54,890)
Straight-line rent adjustment (332,055) (252,759)
Changes in operating assets and liabilities:    
Other assets (211,023) 1,050,221
Deferred tax asset (346,762) 0
Accounts payable and accrued liabilities 60,556 (1,539,727)
Accounts payable and accrued liabilities for the SPAC 652,577 417,975
Accrued real estate taxes 73,212 (61,038)
Net cash provided by operating activities 1,489,839 928,817
Cash flows from investing activities:    
Real estate acquisitions (21,909,963) (15,673,575)
Additions to buildings and tenant improvements (6,663,116) (2,107,505)
Investment in marketable securities (2,161,724) (1,762,095)
Proceeds from sale of marketable securities 2,974,910 2,363,063
Investment of SPAC IPO proceeds into Trust Account (624,998) (134,895,000)
Withdrawals from Trust Account for SPAC taxes 832,480 0
Withdrawals from Trust Account for Redemption of SPAC Shares 137,157,011 0
Deletions / (additions) to deferred leasing costs 7,744 (70,889)
Proceeds from sales of real estate, net 10,698,386 25,768,334
Net cash provided by (used in) investing activities 120,310,730 (126,377,667)
Cash flows from financing activities:    
Proceeds from mortgage notes payable, net of issuance costs 20,804,277 20,288,093
Repayment of mortgage notes payable (10,089,026) (11,958,568)
Payment of deferred offering costs (5,000) (3,201,266)
Distributions to noncontrolling interests, net (1,676,639) (4,412,046)
Proceeds from initial public offering of SPAC 0 134,024,416
SPAC offering non-controlling interest adjustment 0 (1,774,416)
Redemption of SPAC shares (137,157,011) 0
Repurchase of Series A Common Stock, at cost 0 (313,389)
Dividends paid to Series D Preferred Stockholders (2,118,846) (2,152,741)
Dividends paid to Series A Common Stockholders (1,194,635) (3,114,456)
Net cash (used in) provided by financing activities (131,806,866) 127,263,486
Net (decrease) increase in cash equivalents and restricted cash (10,006,297) 1,814,636
Cash, cash equivalents and restricted cash - beginning of period 16,516,725 14,702,089
Cash, cash equivalents and restricted cash - end of period 6,510,428 16,516,725
Supplemental disclosure of cash flow information:    
Income taxes paid $ 533,340 $ 517,902
Non-cash financing activities:    
Potentially convertible common stock for SPAC (in shares) | shares 0 134,895,000
Dividends payable $ 174,011 $ 178,511
Mortgage Notes [Member]    
Supplemental disclosure of cash flow information:    
Interest paid 4,962,458 4,110,288
Series D Preferred Stock [Member]    
Cash flows from financing activities:    
Repurchase of Series D Preferred Stock, at cost (369,986) (122,141)
Non-cash financing activities:    
Dividends payable 174,011 178,511
Conduit Pharmaceuticals Inc [Member]    
Adjustments to reconcile net income to net cash provided by operating activities:    
Net change in fair value marketable securities 23,359,774 0
All Other Than Conduit [Member]    
Adjustments to reconcile net income to net cash provided by operating activities:    
Net change in fair value marketable securities $ (42,664)